Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFIRINOX Plus Ramucirumab vs Placebo in Advanced Pancreatic Cancer
NCT02581215Phase 2Completed
- Start
- Sep 2016
- Primary completion
- Aug 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ramucirumab in pancreatic cancer (PC) (2 arms). Primary endpoint: Progression Free Survival at 9 months. Started Sep 2016; status: completed.
02
Drugs
ramucirumab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02581215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02581215.